| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b5c7ac62800ffaf3eef10a390a9490b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0002 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate |
2002-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ec659d89347ea6a4112f2febb3af1a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a41e44a99ef9d69d13717628f5f69c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2f3d22e610f2df7c93af35f1975b60a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c5da684e973309dcfd0523fb7d2f293 |
| publicationDate |
2003-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1365804-A2 |
| titleOfInvention |
Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent |
| abstract |
Histidine Proline Rich Glycoprotein (HPRG) polypeptides or fragments thereof including pentapeptide fragments and multimers thereof, and other biologically active derivatives of HPRG are anti-angiogenic. These compounds may be used to inhibit angiogenesis or treat a disease or condition in which angiogenesis is pathogenic. These compounds therefore have anti-tumor activity and are used in methods for inhibiting the growth of primary tumors or metastases. Antibodies specific for epitopes of the His-Pro rich domain of HPRG are stimulators of angiogenesis and are useful for promoting neovascularization in pertinent disease states. |
| priorityDate |
2001-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |